A real world study of cough burden and quality of life of UK patients who have undergone evaluation for chronic cough

References

• Kuzniar TJ, Morgenthaler TI, Afessa B, et al. Chronic cough from the patient’s perspective. Mayo Clin Proc. 2007;82(1):56–60. doi: 10.1016/S0025-6196(11)60967-1.
   PubMed Web of Science ®Google Scholar
• Young EC, Smith JA. Quality of life in patients with chronic cough. Ther Adv Respir Dis. 2010;4(1):49–55. doi: 10.1177/1753465809358249.
   PubMedGoogle Scholar
• Morice AH, Jakes AD, Faruqi S, et al. A worldwide survey of chronic cough: a manifestation of enhanced somatosensory response. Eur Respir J. 2014;44(5):1149–1155. doi: 10.1183/09031936.00217813.
   PubMed Web of Science ®Google Scholar
• Chamberlain SAF, Garrod R, Douiri A, et al. The impact of chronic cough: a cross-sectional european survey. Lung. 2015;193(3):401–408. doi: 10.1007/s00408-015-9701-2.
   PubMed Web of Science ®Google Scholar
• Song WJ, Chang YS, Faruqi S, et al. The global epidemiology of chronic cough in adults: a systematic review and meta-analysis. Eur Respir J. 2015;45(5):1479–1481. doi: 10.1183/09031936.00218714.
   PubMed Web of Science ®Google Scholar
• Kubo T, Tobe K, Okuyama K, et al. Disease burden and quality of life of patients with chronic cough in Japan: a population-based cross-sectional survey. BMJ Open Respir Res. 2021;8(1):e000764. doi: 10.1136/bmjresp-2020-000764.
   PubMed Web of Science ®Google Scholar
• Al-Sheklly B, Satia I, Badri H, et al. P5 prevalence of refractory chronic cough in a tertiary cough clinic. Thorax. 2018;73:A98.
   Web of Science ®Google Scholar
• Van den Berg JWK, Baxter CA, Edens M, et al. Definition, characteristics and quality of life of patients with chronic cough from the isala chronic cough clinic in The Netherlands. Eur Respir J. 2021;58(Suppl 65):PA1953. doi: 10.1183/13993003.congress-2021.PA1953.
   Google Scholar
• Takeda N, Takemura M, Kanemitsu Y, et al. Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough: implications of neurogenic and neutrophilic inflammation. J Asthma. 2020;57(11):1202–1210. doi: 10.1080/02770903.2019.1641204.
   PubMed Web of Science ®Google Scholar
• Boulet LP, Coeytaux RR, McCrory DC, et al. Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report. Chest. 2015;147(3):804–814. doi: 10.1378/chest.14-2506.
   PubMed Web of Science ®Google Scholar
• Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: leicester cough questionnaire (LCQ). Thorax. 2003;58(4):339–343. doi: 10.1136/thorax.58.4.339.
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365. doi: 10.2165/00019053-199304050-00006.
   PubMed Web of Science ®Google Scholar
• Cho PSP, Rhatigan K, Fletcher HV, et al. Defining health states with visual analogue scale and leicester cough questionnaire in chronic cough. Eur Resp J. 2021;58:PA3144. doi: 10.1183/13993003.
   Google Scholar
• Kind P, Hardman G, Macran S. UK population norms for EQ-5D. https://www.york.ac.uk/che/pdf/DP172.pdf.
   Google Scholar
• Janssen B, Szende A. Population norms for the EQ-5D. In: szende A, Janssen B, Cabases J, eds. Self-Reported population health: an international perspective based on EQ-5D. Dordrecht (NL): Springer; 2013. p. 19–30.
   Google Scholar
• Smith JA, Kitt MM, Morice AH, et al. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med. 2020;8(8):775–785. (doi: 10.1016/S2213-2600(19)30471-0.
   PubMed Web of Science ®Google Scholar
• McGarvey LP, Birring SS, Morice AH, et al. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022;399(10328):909–923. doi: 10.1016/S0140-6736(21)02348-5.
   PubMed Web of Science ®Google Scholar
• Won HK, Lee JH, An J, et al. Impact of chronic cough on health-related quality of life in the korean adult general population: the Korean national health and nutrition examination survey 2010-2016. Allergy Asthma Immunol Res. 2020;12(6):964–979. doi: 10.4168/aair.2020.12.6.964.
   PubMed Web of Science ®Google Scholar
• Yu CJ, Song WJ, Kang SH. The disease burden and quality of life of chronic cough patients in South Korea and Taiwan. World Allergy Organ J. 2022 ;Sep 515(9):100681. doi: 10.1016/j.waojou.2022.100681.
   PubMed Web of Science ®Google Scholar
• Ternesten-Hasséus E, Larsson S, Millqvist E. Symptoms induced by environmental irritants and health-related quality of life in patients with chronic cough – A cross-sectional study. Cough. 2011;7(1):6. doi: 10.1186/1745-9974-7-6.
   PubMedGoogle Scholar
• Everett CF, Kastelik JA, Thompson RH, et al. Chronic persistent cough in the community: a questionnaire survey. Cough;2007;3:5. doi: 10.1186/1745-9974-3-5.
   PubMedGoogle Scholar
• Morice AH, Millqvist E, Bieksiene K, et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1):1901136. doi: 10.1183/13993003.01136-2019.
   PubMed Web of Science ®Google Scholar
• Morice AH, Birring SS, Smith JA, et al. Characterization of patients with refractory or unexplained chronic cough participating in a phase 2 clinical trial of the P2X3-Receptor antagonist gefapixant. Lung. 2021;199(2):121–129. doi: 10.1007/s00408-021-00437-7.
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Hong B, et al. Patient-Reported burden of chronic cough in a managed care organization. J Allergy Clin Immunol Pract. 2021;9(4):1624–1637.e10. doi: 10.1016/j.jaip.2020.11.018.
   PubMed Web of Science ®Google Scholar
• Cho PSP, Shearer J, Simpson A, et al. Healthcare utilization and costs in chronic cough. Curr Med Res Opin. 2022;38(7):1251–1257. doi: 10.1080/03007995.2022.2065142.
   PubMed Web of Science ®Google Scholar
• Dicpinigaitis PV, Birring SS, Blaiss M, et al. Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. Ann Allergy Asthma Immunol. 2023;130(1):60–66. doi: 10.1016/j.anai.2022.05.003.
   PubMed Web of Science ®Google Scholar
• Irwin RS, Madison JM. Gefapixant for refractory or unexplained chronic cough? JAMA. 2023;330(14):1335–1336. doi: 10.1001/jama.2023.18508.
   PubMedGoogle Scholar
• Birring SS, Morice AH, Dicpinigaitis PV, et al. Reply to weinberger. Am J Respir Crit Care Med. 2023;207(12):1650–1651. doi: 10.1164/rccm.202304-0709LE.
   PubMedGoogle Scholar
• Ilicic AM, Oliveira A, Habash R, et al. Non-pharmacological management of non-productive chronic cough in adults: a systematic review. Front Rehabil Sci. 2022;3:905257.
   PubMedGoogle Scholar